Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Approves Label Expansions for Lynparza, Ultomiris, Keytruda, Tagrisso, and More
August 25, 2022
- 1st Meeting of New Drug Distribution and Pricing Panel Set for Aug. 31
August 25, 2022
- AstraZeneca’s COVID Cocktail Up for Aug. 29 PAFSC Session; Comirnaty Pediatric Booster Too
August 23, 2022
- MHLW to Seek Budget for Integrated Drug Supply Info System for FY2023
August 23, 2022
- MHLW to Boost Orphan Program to Fuel New Drug Development: FY2023 Budget Request
August 23, 2022
- After Repeated Scandals, PMDA Sets Up New Division to Provide GMP Inspection Know-How to Prefectures
August 22, 2022
- Study Group Agrees on Need to Craft Transparent Rules for Use of Pseudonymized Info
August 22, 2022
- Operational Issues of Emergency Approval Scheme Will Be Addressed If Needed: Pharma Bureau Chief
August 19, 2022
- New Panel on Drug Distribution and Pricing Likely to Launch on Aug. 31
August 18, 2022
- AZ’s Asthma Drug Tezepelumab Up for MHLW Panel Review on August 29
August 17, 2022
- Generic Makers Flock to Samsca’s Heart Failure Market after Patent Invalidated; Gx Listing Expected in December
August 16, 2022
- Authorized Generics Approved for Nexium, Samsca, Lipitor, Careram
August 16, 2022
- First Generics for 5 APIs Approved towards December Listing, with 8 Firms for Nexium
August 16, 2022
- MHLW Leaks Personal Info on Intractable Disease Patients
August 16, 2022
- Lilly’s GIP/GLP-1 Receptor Agonist Up for PAFSC Review on August 25
August 15, 2022
- Takashi Hanyuda Tapped as Senior Vice Health Minister
August 15, 2022
- 26 Suspected Violations in Detailing Activities Reported in FY2021: MHLW
August 12, 2022
- Nippon Shinyaku’s MonoVer Iron Deficiency Drug Skips August Listing
August 12, 2022
- Katsunobu Kato Makes Yet Another Comeback as Health Minister
August 10, 2022
- Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…